CLINICAL TRIAL SUMMARY

MDACC Study No:2004-0144 (clinicaltrials.gov NCT No: NCT00714103)
Title:A PHASE I STUDY OF 8-CHLORO-ADENOSINE IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA /SMALL LYMPHOCYTIC LYMPHOMA
Principal Investigator:William G. Wierda
Treatment Agent:8-chloro-adenosine
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest safe dose of
the drug 8-chloro-adenosine that can be given in the treatment of CLL. Another
goal is to learn how effective the drug is at treating leukemia.

Hide details for General InformationGeneral Information

Disease Group:Hematologic Disorder
Phase of Study:Phase I
Treatment Agents:8-chloro-adenosine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None
Supported By:N/A
Return Visit:All treatment will be given at MDACC. Patients will return weekly while
receiving treatment.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults